62 research outputs found
Проведение подготовительных горных выработок с анкерной крепью
В цій статті вперше визначені головні чинники та умови застосування конструкцій анкерного кріплення для виробок, що проводяться для експлуатації в зоні та поза зоною впливу очисних робіт. Наведено типові схеми розташування анкерів у цих конструкціях для виробок, що зберігаються для повторного застосування, та порядок їх вибору.This article was first identified key factors and conditions of using of roof bolting construction
for mine working carried out for using in the zone and outside the zone of impact of treatment
works. The typical schemes of anchors location in these constructions for the mine workings, saving for reuse, and the order of their choice were shown
Recent developments in planet migration theory
Planetary migration is the process by which a forming planet undergoes a
drift of its semi-major axis caused by the tidal interaction with its parent
protoplanetary disc. One of the key quantities to assess the migration of
embedded planets is the tidal torque between the disc and planet, which has two
components: the Lindblad torque and the corotation torque. We review the latest
results on both torque components for planets on circular orbits, with a
special emphasis on the various processes that give rise to additional, large
components of the corotation torque, and those contributing to the saturation
of this torque. These additional components of the corotation torque could help
address the shortcomings that have recently been exposed by models of planet
population syntheses. We also review recent results concerning the migration of
giant planets that carve gaps in the disc (type II migration) and the migration
of sub-giant planets that open partial gaps in massive discs (type III
migration).Comment: 52 pages, 18 figures. Review article to be published in "Tidal
effects in Astronomy and Astrophysics", Lecture Notes in Physic
Moral panic and electric micromobilities: Seeking space for mobility justice
This article was orginally published as: Travers, Scott, N., Reed, K.J., Hall, P., Winters, M., Kwan, G., & Park, K. (2024). Moral panic and electric micromobilities: Seeking space for mobility justice. Sociological Perspectives, 67(1-3), 83-108. https://doi.org/10.1177/07311214231193355This article makes the case that electric micromobilities (EMMs) are the site of a moral panic and employs the lens of mobility justice to explain it. Through analysis of scholarly and media discourse, interviews with, and social media content produced by, EMM riders (eriders), and the auto ethnographic experiences of the lead author as an electric unicycle rider in daily life, as a participant in online and offline “erider” communities, and as a food delivery worker, we reinforce the conclusion that alternate mobilities face an uphill battle in gaining legitimacy and inclusion in transportation policy and infrastructure. While this is not a new finding—alternate mobilities have a long history of being demonized and excluded—this article offers insight into how individuals who find themselves unwitting scapegoats in conflicts over public space consciously engage in deliberate actions to resist EMM panic and achieve greater mobility justice.The author(s) received financial support from the Social Sciences and Humanities Research Council of Canada Knowledge Synthesis Grant Program
Analysis of isometric cervical strength with a nonlinear musculoskeletal model with 48 degrees of freedom
Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings
Background:Antiretroviral regimens with simplified dosing and better safety are needed to maximize the efficiency of antiretroviral delivery in resource-limited settings. We investigated the efficacy and safety of antiretroviral regimens with once-daily compared to twice-daily dosing in diverse areas of the world.Methods and Findings:1,571 HIV-1-infected persons (47% women) from nine countries in four continents were assigned with equal probability to open-label antiretroviral therapy with efavirenz plus lamivudine-zidovudine (EFV+3TC-ZDV), atazanavir plus didanosine-EC plus emtricitabine (ATV+DDI+FTC), or efavirenz plus emtricitabine-tenofovir-disoproxil fumarate (DF) (EFV+FTC-TDF). ATV+DDI+FTC and EFV+FTC-TDF were hypothesized to be non-inferior to EFV+3TC-ZDV if the upper one-sided 95% confidence bound for the hazard ratio (HR) was ≤1.35 when 30% of participants had treatment failure.An independent monitoring board recommended stopping study follow-up prior to accumulation of 472 treatment failures. Comparing EFV+FTC-TDF to EFV+3TC-ZDV, during a median 184 wk of follow-up there were 95 treatment failures (18%) among 526 participants versus 98 failures among 519 participants (19%; HR 0.95, 95% CI 0.72-1.27; p = 0.74). Safety endpoints occurred in 243 (46%) participants assigned to EFV+FTC-TDF versus 313 (60%) assigned to EFV+3TC-ZDV (HR 0.64, CI 0.54-0.76; p<0.001) and there was a significant interaction between sex and regimen safety (HR 0.50, CI 0.39-0.64 for women; HR 0.79, CI 0.62-1.00 for men; p = 0.01). Comparing ATV+DDI+FTC to EFV+3TC-ZDV, during a median follow-up of 81 wk there were 108 failures (21%) among 526 participants assigned to ATV+DDI+FTC and 76 (15%) among 519 participants assigned to EFV+3TC-ZDV (HR 1.51, CI 1.12-2.04; p = 0.007).Conclusion: EFV+FTC-TDF had similar high efficacy compared to EFV+3TC-ZDV in this trial population, recruited in diverse multinational settings. Superior safety, especially in HIV-1-infected women, and once-daily dosing of EFV+FTC-TDF are advantageous for use of this regimen for initial treatment of HIV-1 infection in resource-limited countries. ATV+DDI+FTC had inferior efficacy and is not recommended as an initial antiretroviral regimen.Trial Registration:http://www.ClinicalTrials.gov NCT00084136
Experimental confirmation of efficient island divertor operation and successful neoclassical transport optimization in Wendelstein 7-X
We present recent highlights from the most recent operation phases of Wendelstein 7-X, the most advanced stellarator in the world. Stable detachment with good particle exhaust, low impurity content, and energy confinement times exceeding 100 ms, have been maintained for tens of seconds. Pellet fueling allows for plasma phases with reduced ion-temperature-gradient turbulence, and during such phases, the overall confinement is so good (energy confinement times often exceeding 200 ms) that the attained density and temperature profiles would not have been possible in less optimized devices, since they would have had neoclassical transport losses exceeding the heating applied in W7-X. This provides proof that the reduction of neoclassical transport through magnetic field optimization is successful. W7-X plasmas generally show good impurity screening and high plasma purity, but there is evidence of longer impurity confinement times during turbulence-suppressed phases.EC/H2020/633053/EU/Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium/ EUROfusio
Heparin-resistant thrombin activity in coronary dissection and threatened coronary occlusion during coronary interventions
En Bloc Resection of 3 Vertebra in a Pancoast Patient: Long-Term Stability Using a Free Vascularized Fibular Graft
The Rationale for and Clinical Pharmacology of Prasugrel 5 mg
Prasugrel is a third-generation thienopyridine platelet P2Y12 adenosine diphosphate (ADP) receptor antagonist administered with aspirin for the treatment of patients with acute coronary syndrome (ACS) with planned percutaneous coronary intervention. Prasugrel is administered periprocedurally at an oral loading dose of 60 mg followed by daily maintenance doses (MDs) of 10 mg for most patients and 5 mg for patients weighing &lt;60 kg or aged ≥75 years. Data from a prasugrel phase III study, TRITON-TIMI 38, suggested that a lower MD might be more suitable for patients weighing &lt;60 kg or aged ≥75 years; subsequent pharmacokinetic and pharmacodynamic studies have indicated that prasugrel 5 mg reduced platelet reactivity in these populations to an extent similar to that of prasugrel 10 mg in heavier or younger patients. Clinical experience with prasugrel 5 mg is limited, and additional studies are needed to verify the clinical efficacy and safety of this dose in these challenging populations. © 2016, Springer International Publishing Switzerland
- …
